Inhaled combination therapies for pulmonary fibrosis

Proprietary dry-powder inhaled therapies for pulmonary fibrosis and interstitial lung disease, built on the SPRAYE™ platform.

Investors and Partners

We are evaluating licensing and co-development for selected programs, and ways to formulate third-party pulmonary assets as inhaled products.

For investors

eSpraye is advancing Combination 2, its lead development program, independently, which keeps control of IP, formulation, clinical design and economics. Partnering on the other programs is intended to accelerate them while the lead program progresses.

Financing and program details are shared in direct conversation. Contact us to start one.

For pharma partners
  1. 1License or co-develop an individual eSpraye combination.
  2. 2Apply SPRAYE™ technology and IP to an existing or pipeline molecule.
  3. 3Set up a broader platform or portfolio collaboration.
  4. 4Explore a longer-term strategic combination as the clinical portfolio matures.